Member Info for mulledwine

Thomas A. Nicolette, President & CEO, commented: "With an industry shift towards expedited test results in the clinical laboratory and at the point-of-care, the forthcoming launch of our revolutionary blood cell separator technology within our PIFA platform represents a breakthrough in diagnostic testing. PIFA PLUSS narrows the entire test procedure, inclusive of sample preparation, to a timeline measured in minutes, versus traditional more labour -intensive and slower methods which can involve samples being sent away to external laboratories. The product further demonstrates our continued dedication to technology enhancement and to delivering clinically-relevant information for laboratorians, and the physicians whom they support, in a timely and cost-efficient manner. In addition to the anticipated value this Technology will bring to ABI's portfolio, the adaptability of the Technology may lead to partnerships with other diagnostic firms for use on their own platforms."

Launch of revolutionary PIFA PLUSS PF4 Rapid Assay whole blood technology Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that its patented blood cell separator technology (the "Technology") will be integrated into the Company's PIFA Rapid Assay platform and launched into market in January 2012. The Technology enables the immediate separation of serum (the liquid component of blood) from a patient's finger stick or venous whole blood sample and then introduces the extracted specimen into a rapid assay device to provide a real-time result. In addition, whole blood treated with certain anticoagulants, commonly used in some coagulation laboratories, will now be compatible with the Company's PIFA Rapid Assay platform. The Technology, which fulfills all of the requirements of the FDA for marketability, is designed to be adaptable and can also be applied to other diagnostic testing methodologies. This enhancement drastically improves assay turn-around-time which is critical not only to point-of-care ("POC") screening, but to all in vitro diagnostic testing overseen by the laboratory. In the Company's interim statement of 7 September 2011, the product was referred to as "PIFA POC"; it will now be branded under the trade name PIFA PLUSS to represent the addition of our Serum Separation technology into the PIFA platform. The initial introduction of this product line extension will expand the Company's franchise in the Heparin-Induced Thrombocytopenia ("HIT") rapid testing market. The PIFA PLUSS PF4 Rapid Assay will be uniquely positioned as the only whole blood, disposable screening device for the rapid detection of antibodies which are a major determinant in the pathogenesis of HIT, a life-and limb-threatening complication of treatment with the blood-thinner Heparin. The Company plans to apply the Technology to many of its other diagnostic products, including its infectious disease suite of rapid assays, which includes diagnosis of Chlamydia and Malaria. In the USA, the PIFA PLUSS PF4 Rapid Assay will be sold to end-users exclusively by ABI's direct sales force; the Company is actively seeking partners for non-USA distribution.

http://www.investegate.co.uk/Article.aspx?id=201112060700273983T

Kerr Anderson, Ormonde's Managing Director, said: "Following the very positive initial drilling results at our Zamora Gold Project, which encountered significant gold intersections, we are pleased to have agreed an expanded drilling campaign with our joint venture partner Aurum Mining. This drilling programme, funded by Aurum, has now commenced with the aim of more thoroughly testing and expanding the Facho gold structure."

The Board of Ormonde is pleased to report that following the recent positive gold intersection results from the initial drilling at the Zamora Gold Project in western Spain, an expanded drilling campaign has been agreed with our joint venture partner, Aurum Mining PLC ("Aurum Mining" or "Aurum"), and drilling has now commenced. Key points: · The initial two holes drilled on the "Facho" structure returned significant gold mineralisation: o 12 metres grading 3.4 grammes per tonne ("g/t") gold within an overall interval of 30 metres grading 1.6g/t gold (from 75m depth) and o 10 metres grading 2.1g/t gold (from 102m depth) · A third hole, drilled on an unrelated structure, did not encounter any gold mineralisation. · Following analysis of these initial results the Joint Venture has agreed a new drilling campaign with the intention of testing and expanding the "Facho" structure. · This campaign will include ~2,000m of diamond drilling and it is anticipated that drilling will be complete and assays available during Q1 2012.

http://www.investegate.co.uk/Article.aspx?id=201112060700223431T

Injection moulded plastic products manufacturer Coral Products (CRU) saw profits jump 48% to 1.8 million pounds in the six months ended 31st October. A 29% increase in revenues to 8.66 million pounds as well as a 2.6 percentage point improvement in gross margins to 20.8% led to the increased profit, and marks a significant improvement in the company's finances since its move from the main market to AIM earlier this year. The company commented that the acquisition of Interpack in September had allowed for a greater utilisation of its existing manufacturing capacity. XCAP Securities rates the shares as a "buy" with a price target of 18p, describing the shares as "dirt cheap".The shares jumped 1.25p to 14.5p.

Aberdeen Asset Management (ADN) saw assets under management fall to 169.9 billion pounds as at 30th September, from 178.7 billion pounds at the same time last year. However, the group achieved significant pre-tax profit growth of 78.4% to 224.1 million pounds, benefiting from a high level of new high margin business. The company's earnings per share of 18.7p were 7.5% ahead of Arbuthnot Securities' forecast, and the broker notes a strong balance sheet and dividend yielding 4.3%. Aberdeen shares rose 7.8p to 211.2p.

Millennium & Copthorne (MLC) kept its "buy" rating from Shore Capital on news that real estate developer City Developments had increased its holding in the hotel group to 54.9%. While the broker view a full bid unlikely, it believes that the increased position demonstrates confidence in the quality of the assets. At the current price, Shore feels that investors have access to its core London, New York and Asian assets at book value, with a further 250p worth of property for free. The shares crept up 0.4p to 426.6p.

Brewin Dolphin maintained its "buy" recommendation for residential landlord Grainger (GRI) with a 160p target price. A strong full year performance, with 34% year-on-year operating profit growth and net asset value growth to 216p per share, leaves the group in a strong position says the broker. Additionally, Brewin notes strong cash generation of 254 million pounds, well ahead of previous levels or around 200 million pounds, which provides flexibility in a period of cautious house price growth. The broker also believes that refinancing risk has been removed following the recent extension of debt maturity. Grainger shares edged down 0.9p to 105.9p.

Peel Hunt upgrades from hold to buy, target raised from 125p to 158p.

Michael Page International: Peel Hunt puts rating and 370p target under review.

TUI Travel: Peel Hunt maintains hold and 140p target.

TUI Travel: Evolution Securities retains sell rating and 150p target.

Sorry - last post was somewhat misplaced!

Michael Page International: Peel Hunt puts rating and 370p target under review

Credit Suisse raises price target to 310p from 295p.

Prosperity Minerals (PMHL) retained its "buy" rating from Daniel Stewart, with a 211p target price. The group's stake in Chinese cement business ACC is now worth 70p per share says the broker. Additionally, Daniel Stewart values the firm's iron ore operations at 7p per share, and therefore claims that the real estate business is significantly undervalued. The broker believes that positive news on the pre-sale of residential apartments at Oriental Landmark will provide a trigger to launch the price. The shares dropped 2p to 86p.

Panmure Gordon reiterated its "buy" recommendation for Dolphin Capital Investors (DCI) with a target price of 83p, ahead of tomorrow's third quarter update. The broker expects the real estate investment company to report a net asset value of 164p per share, down from the interim level of 170p due to the impact of currency movements. Panmure notes that development of the firm's four advanced projects is on budget and believes that the current 84% discount to NAV significantly undervalues the company. Dolphin shares inched up 0.25p to 26.75p

Sagentia - Buy at 91p from James Faulkner of WatsHot.com A bargain? Shareholder funds as at 30th June 2011 stood at £24.7 million (compared to a market cap of £38 million) with c.£14 million in property assets and £10.1 million in net cash. The business itself, which generated £3.4 million in operating cashflow during 2010, is in there for very little. I would suggest that one cannot go far wrong paying around 3 times cashflow for such an innovative business with great growth prospects and an international outlook (77% of sales are now derived from overseas). Looking forward, Sagentia "continues to evaluate acquisition opportunities to accelerate the growth of the Group" and it remains "cautiously optimistic about prospects for the year as a whole... providing the confidence to invest in the future development of Sagentia." Any M&A activity should be positive for the shares, especially given the track record of Chairman Martyn Ratcliffe (who owns a 29.9% stake). This is solid value. Buy.